Fig. 5. Anticancer effect of resveratrol in CRC patient-derived organoids. (A) Suppression of organoid viability. Res was treated into 30T and 33T organoids for 7 d, and viability was measured by MTS assay as described in the Materials and Methods. Data represent the mean ± SD (n=6). ***p<0.001 (vs. control, one-way ANOVA with Dunnett’s post hoc test). (B) Morphology of CRC patient-derived organoids (30T and 33T) treated with Res. (C) Change in protein expression levels by Res.
© Biomolecules & Therapeutics
